Related Experiment Video
Updated: Jun 10, 2026
05:31
Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas
Published on: January 26, 2024
Association between urotensin II gene polymorphism and pre-eclampsia
Ebru Dikensoy1, Ozcan Balat, Mete Gurol Ugur
1Department of Obstetrics and Gynecology, Gaziantep University, Gaziantep, Turkey. ebrudikensoy@yahoo.com
Summary
This study found no link between the urotensin II (UTS2) gene S89N polymorphism and pre-eclampsia. Further research is needed to explore other genetic factors in pre-eclampsia development.
Area of Science:
- Genetics
- Obstetrics
- Molecular Biology
Background:
- Pre-eclampsia is a serious pregnancy complication.
- The urotensin II (UTS2) gene plays a role in cardiovascular regulation.
- Genetic variations may influence pre-eclampsia susceptibility.
Purpose of the Study:
- To examine the association between the UTS2 gene S89N polymorphism and pre-eclampsia.
- To determine if a specific genetic variant in the UTS2 gene is a risk factor for pre-eclampsia.
Main Methods:
- Case-control study involving 142 pregnant women (85 with pre-eclampsia, 57 controls).
- Genotyping of the UTS2 S89N polymorphism using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
- Comparison of genotype and allele frequencies between pre-eclamptic and control groups.
Main Results:
- No statistically significant differences in genotype distribution or allele frequencies were found between the pre-eclampsia and control groups.
- Demographic characteristics were similar between the groups.
- Observed genotype counts adhered to Hardy-Weinberg equilibrium.
Conclusions:
- The UTS2 S89N polymorphism is not associated with pre-eclampsia in this cohort.
- Further investigation into other single nucleotide polymorphisms (SNPs) in pre-eclampsia is warranted.
Related Concept Videos
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...